KRAS and non-small cell lung carcinoma: More details of immune checkpoint inhibitors treating NSCLC patients with sensitive gene mutation (not only EGFR and KRAS, but also ALK, BRAF, and the like) in some open-label multicenter randomized controlled trials need to be reported complementarily.